We observed a significant acceleration of the clinical progression in frameshift mutant TP53 gene CLL patients as compared with WTp53 CLL, while missense mutants show a marked trend of faster clinical progression as compared with WTp53 CLL (Supplementary Figure 2). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.